Amrubicin
As of the edition of 20 October 2026, Amrubicin is a small molecule: in active development; acts on TOP2A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 19, 3 stopped early
- Disease areas
- Cancer; Lungs and airways; Blood and lymph; Skin and connective tissue; Heart and blood vessels; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B and 1 company on route A because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Amrubicin.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product1 company is on route A because of Amrubicin.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | P11388 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 11 | 8 | 0 | 2 |
| Phase 3 | 5 | 3 | 1 | 1 |
| All trials | 19 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sumitomo Pharma | Lead sponsor of trials | 2006 to now |
| Bristol Myers Squibb | Lead sponsor of trials | 2006 to now |
| Marubeni Pharmaceuticals | Lead sponsor of trials | 2008 to now |
| SCRI Development Innovations | Lead sponsor of trials | 2009 to now |
| Gilead Sciences | Lead sponsor of trials | 2025 to now |